David Moskowitz appointed Vice President at Verona Pharma

LONDON: Verona Pharma plc has announced the appointment of David Moskowitz to the newly created position of Vice President, Capital Markets Strategy & Investor Relations.

Moskowitz will oversee the Company’s investor relations activities and will also work with the senior leadership team to further develop Verona Pharma’s public market profile.

“We are delighted to welcome David to Verona Pharma,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “His experience and insights make him ideally suited to support our investor relations programme and goals. He will play an instrumental role in forming and implementing our IR strategy as we plan to start Phase 3 trials with first-in-class product candidate, ensifentrine, in 2020.”

Most recently, Mr. Moskowitz performed strategic advisory and investor relations work for emerging biopharmaceutical and molecular diagnostics companies in his private consulting practice. Prior to this role, Mr. Moskowitz served as Vice President, Investor Relations at both Trovagene and Biocept, public molecular diagnostic companies focused on the liquid biopsy testing market. He previously served as Director of Equity Research at Caris & Co. and as Head of Healthcare Research at Friedman Billings Ramsey. During his tenure in the financial services industry, Mr. Moskowitz also held analyst positions at UBS Warburg and Roth Capital Partners. In 2011, he received the StarMine Analyst Award as the top stock picker among U.S. Biotechnology Analysts. He earned his BS in Pharmacy from Rutgers University and his MBA in Finance and Pharmaceutical Industry Studies from Fairleigh Dickinson University.

Tagged , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • RSS Bloomberg